Has Katharine French, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,907 in general payments to Katharine French, MD across 36 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Katharine French, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Katharine French, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Katharine French, MD

Cardiovascular Disease · East Providence, RINPI 1689836371

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 70.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,735, more than ten times the $14 reported in 2022.

$1,907in general payments, 2019–2025

Across 36 payments — averaging $52.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$1K
Abbott$366
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
Pfizer$34
AstraZeneca$14

What the payments were for

Travel & lodging$1,05956%
Food & beverage$83444%
Education$141%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	26	$1,351
Abbott	5	$366
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$141
Pfizer	2	$34
AstraZeneca	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,907 in reported general payments places this provider in the 75th percentile of 86 cardiovascular disease providers in Rhode Island.

See all cardiovascular disease providers in Rhode Island →

Medicare billing

Part B allowed, 2024

$118,830

Medicare patients

919

Services billed

1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	522	$601,796
XareltoRivaroxaban	156	$164,611
JardianceEmpagliflozin	106	$139,026
EntrestoSacubitril/Valsartan	70	$109,895
MultaqDronedarone Hcl	24	$31,365
Praluent PenAlirocumab	26	$22,411
Repatha SureclickEvolocumab	26	$18,515
BrilintaTicagrelor	18	$13,850
Metoprolol Succinate	587	$10,041
Dofetilide	24	$6,969
Atorvastatin Calcium	605	$6,914
Rosuvastatin Calcium	220	$3,641
Diltiazem 24hr Er (Cd)Diltiazem Hcl	131	$3,599
Dabigatran EtexilateDabigatran Etexilate Mesylate	15	$3,287
Flecainide Acetate	52	$2,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$34	$601,796522 claims
AstraZenecaBrilinta	$14	$13,85018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 86 cardiovascular disease providers in Rhode Island.

Other cardiovascular disease in East Providence

Shirlene ObuobiEast Providence$901
Christopher SongEast Providence$438
Daniel LevineEast Providence$360
Ibrahim ElgabryWoonsocket$72K
Ara SadaniantzProvidence$27K
George BourganosWoonsocket$16K
Edward ThomasWarwick$15K
John CavaProvidence$12K
Jeremy LumProvidence$10K
Franklin SchneiderProvidence$8K

See the full list for Rhode Island →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →